COMMUNIQUÉS West-GlobeNewswire

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
29/02/2024
- Phase 2 trial in patients with RAS-mutated mCRC will evaluate onvansertib plus SoC versus SoC alone in the first-line setting - - Pfizer Ignite is responsible for the clinical execution of the trial - - Initial [...]
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
29/02/2024
Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory NHL [...]
ProKidney to Participate in Jefferies Biotech on the Bay Summit
29/02/2024
WINSTON-SALEM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced [...]
Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance
29/02/2024
CANTON, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions [...]
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29/02/2024
-Enrollment Complete in Cohort A of Phase 3, Pivotal, HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy; Announced Successful Interim Futility Analysis; On Track to Report Top-Line Data in Q4 2024- -Upcoming Type- [...]
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results
29/02/2024
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will [...]
Gritstone bio Announces Workforce Reduction
29/02/2024
EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced an approximately 40% [...]
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
29/02/2024
- Announced positive topline data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and frontline TP53 mutant ( [...]
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
29/02/2024
– Plan to initiate the Phase 3 ENLIGHTEN NASH program for non-cirrhotic (F2-F3) and cirrhotic (F4) patients in the first and second quarters of 2024, respectively – – Long-term data from Phase 2b ENLIVEN trial [...]
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
29/02/2024
Record DANYELZA® net product revenues of $ 23.4 million and $84.3 million for Q4 and FY 2023 represents YoY growth of 42 % and 71%, respectively Cash and cash equivalents of $ 78.6 million as of December 31, 2023; [...]
AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement
29/02/2024
VALENCIA, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin [...]
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29/02/2024
XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures; completion of patient enrollment in X-TOLE2 expected in [...]
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
29/02/2024
Registrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt (PC14586), a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a TP53 Y220C [...]
Nextech to Unveil Patient Journey Innovations Driven by AI for Specialty Practices at 10th Annual EDGE User Conference
29/02/2024
TAMPA, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Nextech, a leading provider of clinical and administrative healthcare technology solutions for specialty physician practices, today announced clients will be the first to [...]
Opération de regroupement d'actions
29/02/2024
Communiqué de presse Ecully, le 29 février 2024 – 18h Prise d’effet du regroupement des actions Spineway Spineway annonce la finalisation de l’opération de regroupement de ses actions par échange de 1 action nouvelle de [...]
Reverse stock split
29/02/2024
Press release Ecully, February 29, 2024 – 6:00 p.m. Effective date of the Spineway reverse stock split Spineway announces the completion of the reverse stock split by exchanging 1 new share of 4.00 euros par value for 2 [...]
NTG Nordic Transport Group A/S – Notice to convene the Annual General Meeting 2024
29/02/2024
Company announcement no. 3 – 24 29 February 2024 NTG Nordic Transport Group A/S – Notice to convene the Annual General Meeting 2024 The Annual General Meeting of NTG Nordic Transport Group A/S will be held on Thursday, [...]
Health Advocate Applauds Federal Government in Free Access to Contraceptives for Canadians
29/02/2024
OTTAWA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The Society of Obstetricians and Gynaecologist of Canada (SOGC) applauds the Canadian government on today’s historic announcement to include free access for prescription [...]
Les professionnels de la santé applaudissent le gouvernement fédéral pour l'accès gratuit aux contraceptifs pour les Canadiens
29/02/2024
OTTAWA, 29 févr. 2024 (GLOBE NEWSWIRE) -- La Société des obstétriciens et gynécologues du Canada (SOGC) applaudit l’annonce historique du gouvernement canadien visant à inclure l'accès gratuit aux méthodes [...]

Pages